Jim Cramer on Merck & Co.: “If We’re Really Going Into an Oil Shock-Induced Slowdown, I Think This One’s Likely an Outperformer””

Core Viewpoint - Merck & Co., Inc. is viewed positively due to its strong performance and strategic acquisition, despite facing market challenges such as higher energy costs and economic uncertainty [1][3]. Stock Performance - Merck has rallied 39% since the end of October, maintaining an uptrend with higher highs and higher lows [1]. - The stock recently traded at approximately $119, with a nearly 3% yield [2]. Market Sentiment - Money managers are actively accumulating Merck shares, indicating strong bullish sentiment as reflected in the Chaikin Money Flow [1]. - Recent sell-offs of 3% to 8% have been seen as ideal entry points for investors [2]. Future Outlook - Analysts predict that Merck could reach $130 by year-end, positioning it as a potential outperformer amid economic slowdowns [3]. - The company is acquiring a clinical-stage cancer drug company for $6.7 billion, which is expected to enhance its portfolio despite the target company not currently generating earnings [3].